Table 1 Correlations between circNFIX expression and clinical characteristics in glioma patients
From: CircNFIX promotes progression of glioma through regulating miR-378e/RPN2 axis
Clinicopathologic features | N (%) | Relative CircNFIX level | P value | |
|---|---|---|---|---|
High (%) | Low (%) | |||
Total cases | 64 (100.0) | 36 (56.3) | 28 (43.7) | Â |
Age (years) | 0.7647 | |||
  ≥ 45 | 40 (62.5) | 22 (55.0) | 18 (45.0) |  |
  < 45 | 24 (37.5) | 14 (58.3) | 10 (41.7) | |
Gender | 0.4363 | |||
 Male | 37 (57.8) | 20 (54.1) | 17 (45.9) |  |
 Female | 27 (42.2) | 16 (59.3) | 9 (40.7) | |
WHO grade | 0.0177 | |||
 I-II | 26 (40.6) | 10 (38.5) | 16 (61.5) |  |
 III-IV | 38 (59.4) | 26 (68.4) | 12 (31.6) | |
Tumor size (cm) | 0.0262 | |||
  ≥ 3 | 36 (56.3) | 23 (63.9) | 13 (36.1) |  |
  < 3 | 28 (43.7) | 13 (46.4) | 15 (53.6) | |
Tumor location | 0.5239 | |||
 Supratentorial | 43 (67.2) | 23 (53.5) | 20 (46.5) |  |
 Subtentorial | 21 (32.8) | 13 (61.9) | 8 (38.1) | |